- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04939103
TRUS-FNA For The Prediction Of pCR After Neoadjuvant Treatment In Rectal Cancer
TRUS-FNA Versus MRI, CT, Enteroscopy, Superficial Biopsy, TRUS For The Prediction Of pCR After Neoadjuvant Treatment In Rectal Cancer
Colorectal cancer is one of the most malignancies worldwide. The dominant clinical research strategy of LARC includes neoadjuvant chemoradiotherapy before radical surgery followed combined with adjuvant treatment. Approximately 15% to 20% of the patients after nCRT can achieve a pathologic complete response (pCR)---no residual tumor is reported at histology after a standard resection. Some researchers suggest that those patients with pCR can be spared the morbidities of surgery instead by a nonoperative approach---watch- and-wait(W&W). However, neither FDG-PET, MRI, CT, nor enteroscopy can accurately determine a pCR.
EUS-FNA has been an important technique for the diagnosis of rectal cancer for its high accuracy and little harm. However, data on the TRUS-FNA for the cytologic diagnosis of pCR in rectal cancer is scarce. Our hypothesis is that adding transrectal ultrasound-guided fine needle aspiration (TRUS-FNA) compared with enteroscopy , MR, and CT alone can improve the accuracy of predicting pCR after nCRT.Therefore, the aim of the study is to assess the performance characteristics of EUS-FNA in this setting.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Following the neoadjuvant treatment of rectal cancer, appropriately 15-20%of patients receiving neoadjuvant treatment can achieve pathological complete response: a condition of no tumor cell detected in surgical specimens, which usually suggests improved oncology outcomes. In 2004, Habr-Gama, A et al. proposed that surgical resection may not increase overall and disease-free survival in these patients and lead to an increased risk of surgical complications and permanent stoma. Therefore, they suggested that nonoperative treatment, which is now referred to as "watch-and-wait"--patients with clinical complete response (cCR) can avoid unnecessary surgery and be managed by strict follow-up and observation alone. A series of studies have shown impressive survival outcomes in patients who received nonoperativetreatment:85-93% and 82-94% in 5-year overall survival and disease-free survival, respectively. Also, in case of relapse, the rate of successfully performed salvage surgery was 80-91%.
However, determining pCR after neoadjuvant treatment for distal rectal cancer remains a dilemma for clinicians. Different imaging modalities, including digital rectal examination (DRE), fludeoxyglucose positron emission tomography (FDG-PET), Computed Tomography (CT), magnetic resonance imaging (MRI), transrectal ultrasound (TRUS) and endoscopy have been well evaluated for the efficacy of predicting pCR. In contrast, none of them proved to be reliable.
Duldulao et al. found that after neoadjuvant treatment, rectal tumor cells are distributed preferentially in the muscularis of the bowel wall while few in the mucosa. That is why superficial biopsies were inadequate, and full-thickness apparitions on tumor focus may provide adequate sampling to rule out malignancy for all stages of rectal cancer after neoadjuvant treatment. Therefore, fine-needle aspiration assisted with TRUS (TRUS-FNA), which can harvest a whole layer of the bowel wall, has shown obvious advantages in this setting.
Although widely used in clinical practice, studies regarding the application of TRUS-FNA in predicting pCR after preoperative therapy of rectal cancer were scarce. We hypothesized that TRUS-FNA could improve the clinical practice of identifying patients achieving pCR after neoadjuvant treatment. Accordingly, we conducted this prospective study to evaluate the efficacy of TURS-FNA, compared with other imaging modalities, TRUS, MRI, CT, enteroscopy, and superficial biopsy, in predicting pCR of rectal cancer after neoadjuvant treatment.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Guangdong
-
GuangZhou, Guangdong, Kina
- The Sixth Affiliate Hospital of Sun Yat-Sen University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- a new diagnosis of histologically confirmed rectal adenocarcinoma
- tumor located below the peritoneum reflex
- over 18 years old
- T1-4,N0-2,M0 before nCRT
- complete nCRT treatment
- ASA>III or ECOG>1
- informed consent
Exclusion Criteria:
- multiple primary colorectal cancer
- the history of malignant tumor,IBD,FAP
- the history of chemoradiation treatment or resection of rectal tumor
- actue abdomen disease requiring emergency surgery
- not be able to tolerate surgery with severe organ dysfunction
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
1
Those patients with rectal cancer after neoadjuvant treatment and completed the examination of TRUS-FNA, TRUS, CT, MR, enteroscopy and superficial biopsy
|
Transrectal Ultrasound Guided Fine Needle Aspiration for rectal tumor
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
the accuracy of predicting pCR after nCRT
Tidsramme: 25/05/2021-25/05/2022
|
The primary endpoint was the predictive yield of TRUS-FNA for pathological complete responses after neoadjuvant treatment.
|
25/05/2021-25/05/2022
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: luo yanxin, MD,PHD, the sixth affiliated hospital of Sun Yet-Sen University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- luoyanxin
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Endetarmskræft
-
Institut BergoniéAfsluttetMedium og Lower Rectal CancerFrankrig
-
Fundación de investigación HMSyntax for Science, S.LAfsluttetLocally Advanced Rectal Cancer (LARC)Spanien
-
King Faisal Specialist Hospital & Research CenterAfsluttetColon Rectal Cancer Duke Stage StagevalSaudi Arabien
-
Austrian Breast & Colorectal Cancer Study GroupAfsluttetRectal Cancer Dukes B, Dukes CØstrig
-
University Health Network, TorontoAfsluttet
-
Sir Run Run Shaw HospitalAktiv, ikke rekrutterendeMSS Locally Advanced Rectal AdenocarcinomaKina
-
Sunnybrook Health Sciences CentreUniversity of Toronto; Sunnybrook Research InstituteAfsluttetRectal Neoplasma Carcinoma in Situ AdenocarcinomaCanada
-
Philips HealthcarePhilips Electronics Nederland B.V. acting through Philips CTO organizationAfsluttetMalignt lymfom i lymfeknuder i lyskeregionen | Malignt lymfom af lymfeknuder i aksillært | Malignt lymfom af lymfeknuder i livmoderhalsen | Karcinom i parotidkirtlen | Colon Rectal Cancer Tubulovillous Adenocarcinoma | Tumor af blødt væv i hoved, ansigt og halsHolland
-
Stanford UniversityAfsluttetGastrointestinale neoplasmer | Kræft i bugspytkirtlen | Spiserørskræft | Anal kræft | Hepatobiliær neoplasma | Gastroøsofageal kræft | Galdeblærekarcinom | Leverkarcinom | Galdeblærekræft | Gastrointestinal stromal tumor (GIST) | Karcinom i tyktarmen | Gastrisk (mave) kræft | Galdevejscarcinom | Colon Rectal Cancer AdenocarcinomForenede Stater
Kliniske forsøg med TRUS-FNA
-
Johns Hopkins UniversityNational Institutes of Health (NIH)Rekruttering
-
University of DundeeNHS Tayside; Chief Scientist Office of the Scottish Government; Prostate... og andre samarbejdspartnereAfsluttetProstatakræftDet Forenede Kongerige
-
Johns Hopkins UniversityAfsluttet
-
Saskatchewan Health Authority - Regina AreaAfsluttetProstatakræftCanada
-
Institut Paoli-CalmettesExact ImagingUkendt
-
University of ArizonaSuspenderetProstatakræft | Prostata AdenocarcinomForenede Stater
-
Amphia HospitalUkendt
-
American Society for Gastrointestinal EndoscopyMidwest Biomedical Research FoundationUkendtEt randomiseret kontrolleret forsøg med endoskopisk ultralydsstyret aspiration med og uden en stiletMediastinal eller intraabdominal lymfadenopati, | Bugspytkirtelmasser, | Venstre binyremasse, | Gastrointestinale submucosale læsioner, og | LevermasserForenede Stater
-
Bin ChengAfsluttetAutoimmun pancreatitisKina
-
Kashani Social Security HospitalUkendtPalpabel brystmasseIran, Islamisk Republik